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ObjectiveaaWith respect to the pharmacotherapy of social anxiety disorder (SAD), it has been suggested that treatment duration is an 
important factor that can significantly predict responses. The present study aimed to compare the treatment adherence of SAD patients 
who were taking either SSRIs or reversible inhibitors of MAO-A (moclobemide) by measuring treatment duration and all-cause discon-
tinuation rates of pharmacotherapy in a natural clinical setting.
MethodsaaWe retrospectively analysed the data of 172 patients diagnosed with SAD. Depending on their medication, we divided the 
patients into two groups, SSRI (n=54) or moclobemide (n=118). The expected number of all-cause discontinuation every 2 weeks after 
starting treatment was calculated by life table survival methods. A multi-variable Cox proportional hazard regression was used to ana-
lyze the potential influence of explanatory variables. 
ResultsaaTreatment duration was significantly longer in the SSRI group [46.41±56.96, median=12.0 (weeks)] than in the moclobemide 
group [25.53±34.74, median=12.0 (weeks), Z=2.352, p=0.019]. Overall, all-cause discontinuation rates were significantly lower with SS-
RIs (81%) than moclobemide (96%, χ
2=4.532, p=0.033).
ConclusionaaThe SSRI group had a longer treatment duration and lower all-cause discontinuation rate than moclobemide. Further, 
only the type of medication had a significant effect on all-cause discontinuation rates and therefore, we could predict better treatment 
adherence with the SSRIs in the treatment of SAD.                                                                                           Psychiatry Investig 2012;9:73-79
Key Wordsaa  Social anxiety disorder, SSRI, Moclobemide, Treatment adherence, All-cause discontinuation.
INTRODUCTION
The clinical importance of social anxiety disorder (SAD, 
also known as social phobia) has increased gradually due to 
the high prevalence and significant impairments in patients’ 
social, educational, and physical functioning.1-3 The onset of 
SAD typically occurs in the first decade of a patient’s life, and 
because of SAD’s long-lasting, disabling symptoms, with var-
ious comorbidities, the disorder’s clinical course is usually chron-
ic and unremitting.4,5
To date, clinicians and researchers have used various anti-
depressants for treating and studying SAD. Until recently, ir-
reversible monoamine oxidase inhibitor (MAOI) phenelzine 
was considered the best-established and, possibly the most 
efficacious pharmacologic treatment option for SAD.6-8 How-
ever, MAOIs require patients to follow strict diet restrictions 
in order to avoid severe hypertensive crises after ingestion of 
tyramine-rich food, such as a cheese or a Kimchi, especially 
in Korea; thus, MAOIs’ general tolerability may be a concern 
over both short- and long-term treatment.9 For such reasons, 
clinicians tend to prefer reversible inhibitors of monoamine 
oxidase A (RIMAs) rather than MAOIs in Korea. Among the 
RIMAs, moclobemide has been less likely to be associated 
with hypertensive crises,9 and has demonstrated superior ef-
ficacy to placebo in some,8,10 but not all double-blind stud-
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ies.11,12 In this respect, selective serotonin reuptake inhibitors 
(SSRIs) have provided another possibility for the pharmaco-
therapy of SAD. As such, the efficacy of SSRIs was superior to 
placebo13-15 and similar to the efficacy of moclobemide.16
In the treatment of other anxiety disorders, there is evi-
dence that certain factors, such as earlier age of onset or hav-
ing a comorbid disorder, might play roles as negative predic-
tors of response to pharmacotherapy;17,18 however, there is 
little available data about predictors of response in SAD. The 
treatment duration has been reported to be one of the most 
important clinical factors for successful treatment in the 
pharmacotherapy of SAD.19 Previous studies4,8,20,21 using 
MAOI in a long term follow-up also suggested that sufficient 
treatment duration is important in relapse prevention. Howev-
er, there has been little available data directly comparing 
treatment duration between MAOIs and other drugs in SAD 
in terms of treatment adherence. 
An analysis of a large group of SAD patients treated with 
the paroxetine demonstrated that only treatment duration 
significantly predicted treatment response.1 Therefore, adher-
ence to pharmacotherapy is critical in order to obtain suc-
cessful clinical outcomes in SAD. For these reasons, it might 
be very important to choose the right medication, one which 
has good efficacy and tolerability over a long period of treat-
ment.
There has been evidence that, despite MAOIs’ good effica-
cy, clinicians no longer consider non-selective MAOIs as 
first-line or maintenance therapy due to several limitations in 
their use. Therefore, moclobemide and SSRIs which have 
fewer limitations16,22 than non-selective MAOIs have been 
recently prescribed as the first-line medication in SAD. Al-
though both moclobemide and SSRIs demonstrated superior 
efficacy to placebo in SAD,23 there has been little available data 
comparing their treatment duration, which is important fac-
tor for successful pharmacotherapy in SAD.1 Based on these 
findings, we compared treatment durations and all-discon-
tinuation rates retrospectively in SAD patients who were tak-
ing either SSRIs or moclobemide in a natural clinical setting. 
 
METHODS
Participants 
The current study was approved by the ethics committee 
of Kangbuk Samsung Hospital. The participants’ information 
was gathered retrospectively from medical records from the 
Social Phobia Clinic at Kangbuk Samsung Hospital. The di-
agnosis of SAD was made by a well-experienced psychiatrist 
(the corresponding author, Dr. Oh KS) through a clinical in-
terview according to the Diagnostic and Statistical Manual of 
Mental Disorders 4th edition (DSM-IV)24 and confirmed by the 
Mini International Neuropsychiatric Interview (MINI).25 Clini-
cal data for patients whose pharmacotherapy for SAD had 
started between January, 2005 and December, 2007 in an 
outpatient clinical setting were evaluated in the current study. 
If his or her primary diagnosis was SAD, we included pa-
tients with comorbidity for other psychiatric disorders, such 
as other anxiety disorders and/or mood disorders which were 
also diagnosed in the same manner as mentioned above. A 
total of 264 patients’ data were collected, and we excluded 
any patient with a past history or current diagnosis of other 
psychotic disorders (n=2), a significant medical illness (n=3), 
a neurological condition (n=1), or other Axis I primary psychi-
atric disorders (n=26). As a result, 232 SAD patients remained, 
and among them, data for 172 patients who were treated 
with SSRIs or moclobemide were analysed in this study. 
Pharmacotherapy and measures 
Well-experienced psychiatrists treated all patients with ei-
ther SSRIs or moclobemide in flexible doses, based on his 
clinical judgment. The SSRIs used in this study included par-
oxetine, sertraline, and escitalopram. Escitalopram is ap-
proved for the pharmacotherapy of SAD in Korea by the Ko-
rea Food and Drug Administration (KFDA) unlike in the 
U.S.A. Because this study was an observational study in a nat-
ural clinical setting, there was no limitation regarding the use 
the benzodiazepines and/or the beta-blockers based on the 
psychiatrist’s judgement. 
We measured treatment duration as the time to discontin-
uation of medications in weeks. Further, we defined all-cause 
discontinuation as patients who had stopped or switched 
their current medication for whatever reason, which was 
made by his or her prescribed psychiatrist, although we did 
not define “termination of treatment” in this study. 
All-cause discontinuation is a composite measure of 4 com-
ponents, which consisted of lack of pharmacological efficacy, 
drug tolerability, clinician decision, and patient decision.26 
Based on Stoup and colleagues,26 the original concept of the all-
cause discontinuation was used to compare the effectiveness of 
antipsychotic drugs in schizophrenia patients, given that 
these patients stop or change medication frequently, and that 
it is hard to measure many individual factors which caused 
discontinuation of treatment.27 Despite some of the limita-
tions,27 the concept of all-cause discontinuation is a mean-
ingful clinical measurement which reflected both efficacy 
and side effects for both the clinician and patients. We com-
pared not only the overall all-cause discontinuation rates be-
tween the SSRI and the moclobemide groups, but also com-
pared the proportion of all-cause discontinuation at 4, 12, 24, 
48, and 96 weeks after starting medication.   SW Lim et al. 
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Data analysis
First, we compared the data descriptively between the SSRI 
and moclobemide groups. We used a Pearson’s chi-square 
test to compare categorical demographic profiles and a Mann 
Whitney U-test to examine differences in continuous vari-
able characteristics, such as age, onset age, and treatment du-
ration. Results have been expressed as means±SD for quanti-
tative variables or as percentages for qualitative variables.
In order to compare the observed number of all-cause dis-
continuation with what would be expected between the SSRI 
and moclobemide groups, the expected number of all-cause 
discontinuation every 2 weeks after starting medication was 
calculated under the assumption that each patient’s risk of 
discontinuation would be equal to the risk of the general 
population. To analyse this risk, life table survival methods 
were used.28 Life table survival curves were generated to 
quantify the time to each medication discontinuation or 
switching, and to compare the survival curves between two 
medication groups during the total treatment period after 
starting medications. Differences in survival curves for both 
groups were compared using the Wilcoxon statistic (Figure 1). 
Lastly, the potential influence of various explanatory vari-
ables on all-cause discontinuation after starting medication 
was investigated using a multi-variable Cox proportional 
hazard regression test.29 We did a regression analysis with all-
cause discontinuation as the dependent variables and items 
including type of drug (SSRIs versus with moclobemide), 
gender, education level, employment status, marital status, 
onset age, and comorbidiy (depression, anxiety, and others) 
as the independent variables (Table 3). SPSS version 12.0 for 
Microsoft Windows was used for these analyses, and the lev-
el of statistical significance was set at p=0.05. 
RESULTS 
Of 172 patients, 54 (31.40%) were treated with SSRIs, which 
included paroxetine (n=41, 75.93%), escitalopram (n=12, 
22.22%), and sertraline (n=1, 1.86%). The remaining 118 pa-
tients received moclobemide only (68.60%). 
Most patients in the current study were in the 17-69 age ran-
ge, and the mean age of all patients was 35.02±12.08 years. 
Figure 1. Proportion of patients without all-cause discontinuation 
over the treatment course in the SSRI and Moclobemide groups
SSRI: Selective Serotonin Reuptake Inhibitor.
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Table 1. Demographic and clinical characteristics of subjects in the SSRI and Moclobemide groups
SSRI (N=54) Moclobemide (N=118) Statistical 
p-value
N (%) or mean±SD N (%) or mean±SD value
Gender (male) 34 (62.96) 79 (69.30) 0.261† 0.609
Age (years) 32.87±12.37 36.01±11.86 1.740‡ 0.082
Education (≥13 years) 23 (42.59) 73 (61.86) 5.579† 0.018*
Employment (no) 11 (20.37) 10 (8.47) 4.602† 0.032*
Marital status (married) 31 (57.41) 49 (41.53) 3.669† 0.055
Age of onset (years) 23.83±11.50 20.61±9.36 -1.972‡ 0.085
Subtype (generalized) 23 (42.59) 51 (43.22) 0.006† 0.938
Comorbidity
All comorbidities 34 (62.96) 43 (36.44) 10.539† 0.001*
Depression 15 (44.12) 26 (60.47)
Anxiety 16 (47.06) 9 (20.93)
Others 3 (8.82) 8 (18.60)
Duration of treatment (weeks) 46.41±56.96 25.53±34.74 -2.352‡ 0.019*
*p<0.05, †chi-square test (χ2), ‡mann-whitney U test (Z). SSRI: Selective Serotonin Reuptake Inhibitor, SD: standard deviation 76  Psychiatry Investig 2012;9:73-79
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There were no significant differences between the SSRIs and 
moclobemide groups with regard to gender and mean age 
(Table 1). We found a significant difference in education level 
between SSRI-treated patients and moclobemide-treated pa-
tients (χ2=5.579, p=0.018), with SSRI-treated patients having 
a significantly lower rate of high-school graduation (n=23, 
42.59% vs. n=73, 61.86%). There was also a significant differ-
ence regarding employment, with the SSRI group having 
more employed participants than the moclobemide group 
(n=11, 20.37% vs. n=10, 8.47%, χ2=4.602, p=0.032; Table 1). 
Among the clinical characteristics, the mean onset age of 
all patients was 21.62±10.16 years, and there was no signifi-
cant difference in mean onset age between the SSRI and mo-
clobemide groups (Z=-1.721, p=0.085). Upon classifying SAD 
into generalized and non-generalized subtypes 24, we found 
no significant difference between the two groups regarding 
subtype distribution (χ2=0.006, p=0.938); however, SSRI-
treated patients had more comorbidities than the moclobe-
mide group, and this was statistically significant (n=34, 62.96% 
vs. n=43, 36.44%; χ2=10.539, p=0.001). The most common 
comorbidity of the SSRI group was other anxiety disorders 
(47.06%), while in the moclobemide group, depression was 
most common (60.47%). Based on the Mann Whitney U-test, 
we found a significant difference in treatment duration be-
tween the two groups, with the SSRI group showing a longer 
duration (46.41±56.96 vs. 25.53±34.74 weeks; Z=-2.352, 
p=0.019; Table 1). 
Figure 1 shows the survival curves for time to all-cause dis-
Table 3. Hazard ratio of all-cause discontinuation during an observation period for patients in the SSRI and Moclobemide groups
Variables
All-cause discontinuation
p-value HR 95% CI
Medication
Moclobemide (reference: SSRIs) 0.008 1.707 1.148-2.538
Gender
Female (reference: male) 0.678 0.928 0.654-1.318
Education
≥13 years (reference: <13 years) 0.974 1.006 0.708-1.429
Employment
Yes (reference: none) 0.382 1.254 0.755-2.084
Marital status
Married (reference: separated, divorced or widowed) 0.662 1.084 0.756-1.555
Age of onset
≥18 years (reference: <18 years) 0.979 1.005 0.715-1.412
Comorbidity (reference for each class: no disorder) 0.156
Depression 0.052 0.052 0.003-1.031
Anxiety 0.597 1.224 0.579-2.586
Others 0.621 1.226 0.546-2.757
HR: hazard ratio, CI: confidence interval, SSRI: Selective Serotonin Reuptake Inhibitor
Table 2. Life-table survival analysis in the SSRI and Moclobemide groups
Interval 
(weeks)
SSRI  Moclobemide 
Wilcoxon χ
2 df p-value
Entering 
interval 
(N)
Withdrawing 
during 
interval (N)
Cumulative
proportion
surviving (%)
Entering
interval
(N)
Withdrawing 
during
interval (N)
Cumulative
proportion
surviving (%)
0
4
12
24
48
96
54 0 100 118 0 100
48 6 89 94 24 80 2.185 1 0.139
33 11 61 63 55 54 4.532 1 0.073
27 27 50 39 79 33 2.943 1 0.086
21 33 39 15 103 13 5.543 1 0.019
7 47 13 8 115 6 5.509 1 0.019
SSRI: Selective Serotonin Reuptake Inhibitor   SW Lim et al. 
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continuation between the SSRI and moclobemide group. The 
current study’s overall number of all-cause discontinuation 
was 148 (86.05%). The overall all-cause discontinuation rate 
was 81% and 96% for the SSRI moclobemide groups, respec-
tively. Although both groups showed relatively high all-cause 
discontinuation rates, the overall all-cause discontinuation 
rate was significantly lower for the patients in the SSRI group, 
compared with the patients with the moclobemide group 
(χ2=4.532, p=0.033). That is, the SSRI treatment group had 
better treatment adherence than the moclobemide group. 
Median times to all-cause discontinuation were 24.0 weeks 
and 13.33 weeks for the SSRI and moclobemide groups, respec-
tively. 
A comparison of cumulative surviving proportion at some 
point during the treatment period in the SSRI and moclobe-
mide group has been provided in Table 2. There was no signif-
icant difference for the cumulative surviving proportion 
within 12 weeks, which indicated a relative early phase of 
treatment between the two groups. However, the cumulative 
surviving proportions were significantly different between 
the SSRI and moclobemide group at weeks 48 (39% vs. 13%, 
χ2=5.543, p=0.019) and 96 (13% vs. 6%, χ2=5.509, p=0.019), in-
dicating a relatively late phase of treatment. 
Table 3 presents the results of a multi-variable hazard mod-
el. Seven explanatory variables were investigated with respect 
to possible effects on the hazard of all-cause discontinuation 
in the observation period as mentioned above. The only sig-
nificant variable that influenced all-cause discontinuation 
was the type of medication (HR=1.707, 95% CI=1.148-2.538, 
p<0.008). In particular, 3 variables (education level, employ-
ment status, and comorbidity) were statistically different be-
tween the SSRI and moclobemide groups in a comparison 
analysis which did not significantly influence on all-cause 
discontinuation. Among the comorbidity, although depres-
sion, anxiety, and other psychiatry disorders had no statisti-
cally significant effect on all-cause discontinuation, patients 
with depression showed a tendency of premature treatment 
termination (HR=0.052, 95% CI=0.003-1.031, p=0.052).
DISCUSSION 
In current study, patients treated with SSRIs had statisti-
cally significant longer treatment durations than those treat-
ed with moclobemide. We also observed that the group treat-
ed with SSRIs had significantly lower rates of all-cause 
discontinuation than the moclobemide group suggesting ad-
herence of the SSRIs could be better than the moclobemide 
in the pharmacotherapy of SAD. If we consider this study as 
an extension of an earlier study by Stein et al.,1 we could expect 
better clinical outcomes possibly with the SSRIs than with 
moclobemide in the treatment of SAD, although we did not com-
pare the efficacy or the response directly between two groups.
In clinical trials with antidepressants, participant discon-
tinuation commonly occurs for several reasons. There are 
early and late discontinuation, according to the point at which 
participants discontinue at an acute phase or at a relatively 
late point in the treatment period and there may be differ-
ences in the reasons between two cases. For example, adverse 
drug effects may lead to relatively early termination during 
the first few weeks.30 Generally, insufficient response could 
cause a participant to stop a treatment near the end of the 
treatment process.31,32 Besides these factors, potential discon-
tinuation risk can be viewed as the result of complex interac-
tion among several predisposing factors, such as demo-
graphic, social, economic, and treatment related factors, such 
as comorbidity, past treatment history, and psychosocial in-
terventions. With respect to these, all-cause discontinuation 
which was mentioned early in this article is a rather suitable 
outcome measurement for the comparison of treatment dis-
continuation in the current study. Further, if different all-cause 
discontinuation rates arose among the medication groups, it 
would be important to identify the crucial causes for discon-
tinuation.26 As in other clinical trials, most patients treated 
with the antidepressants discontinue the treatment because 
of adverse effects33 and thus, we considered the differences in 
tolerability between the two groups. 
Because in current study we did not directly assess adverse 
effects in both groups, we could only infer reasons for discon-
tinuation or switching drugs from the cumulative surviving pro-
portion at 4, 12, 24, 48, and 96 weeks of observation. In the 
current study, the fact that about 89% of patients treated with 
SSRIs and 80% of patients treated with moclobemide persist-
ed with therapy for 4 weeks (p=0.139), which represents the 
acute treatment phase, suggested that perhaps adverse effects 
do not cause patients to discontinue treatment.31 Although 
some participants might have had adverse effects in the rela-
tively late period of treatment, we did not directly assess 
them.
In this study, the moclobemide group exhibited lower sur-
viving proportions at weeks 48 and 96 than the SSRI group. 
However, we cannot postulate that this difference is related 
with varying efficacy between the two groups because there 
was no direct measurement of efficacy or response. There-
fore, we can only assume that the SSRI group had better treat-
ment adherence than the moclobemide group.
In a Cox proportional hazards model, our study showed that 
the overall all-cause discontinuation rate was significantly in-
fluenced by the type of medication and not by other variables, 
such as education level, employment status, and comorbidity, 
which were significantly different in a simple comparison 78  Psychiatry Investig 2012;9:73-79
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analysis. Although education level was not related to overall 
treatment or all-cause discontinuation in the current study, 
there has been evidence of an association between 16 or 
more years of education nd a lower risk of discontinuation 
provided by care provided by mental health professionals oth-
er than psychiatrists.34,35 To this point, there has been little evi-
dence that discontinuation rates are associated with employ-
ment status; however, there has been evidence that high-
income patients are less likely than patients with low-average 
incomes to discontinue treatment especially in the later peri-
od of treatment process.36 Therefore, in evaluating discontin-
uation risk associated with employment status, consideration 
should be given to factors beyond simply having an occupa-
tion or not; however, the current study assessed only employ-
ment status. 
In this study, the SSRI group had a higher proportion of co-
morbidity than the moclobemide group and thus, we put co-
mobidity into the Cox proportional hazard model as a possi-
ble factor which could independently affect the all-cause dis-
continuation rate. However, no association of comobidity with 
the all-cause discontinuation rate was found in current study. 
In a further analysis, mood and anxiety disorder appeared to 
exert little influence on the propensity to all-cause discontin-
ue. Generally, there could be a tendency that patients with co-
morbid psychiatric disorder were more likely than patients 
with only one disorder to leave a treatment process in the gener-
al sector in the early phase of treatment.37 We found that only 
depression may be possibly associated with the all-cause dis-
continuation rate in the current study. 
In interpreting these findings, we note several limitations. 
First, the present study involved a relative small patient sam-
ple with no strict control of the patient population. In partic-
ular, there are two major points regarding the lack of control 
over patient population. One is another drug’s potential effects 
and the other is the severity of social anxiety symptoms. Evi-
dence has supported that benzodiazepines or beta-blockers 
are considered effective treatment options in the manage-
ment of SAD;38 however, we did not analyze the confounding 
effect of these medications in this study. Also, cognitive behav-
ioral therapy or other psychosocial interventions have been 
reported to influence the treatment response;39 however, we 
did not consider such effects in our retrospective design. Fur-
thermore, as we performed no assessment of the severity of 
social anxiety symptoms at baseline, a particular group could 
include more patients with severe or mild symptoms. A cli-
nician’s attitude toward treatment could be varied with 
symptom severity, and this could have possibly influenced 
treatment persistence. Secondly, the present study did not in-
clude clinical parameters for adverse drug events or treat-
ment responses. Generally, researchers have estimated medi-
cation adherence or all-cause discontinuation rates by using 
various methods, such as the length of therapy method (LOT) 
metric, which estimates time to all-cause discontinuation from 
data sources like patient self-reports, computerized pharmacy 
records, or pill counts21,40,41 In particular, our study is limited 
by the fact that we indirectly inferred the reason for all-cause 
discontinuation via some points of observation. Similarly, the 
efficacy of both medications could not be confirmed directly 
from the data. Third, as a naturalistic study using a second-
ary data analysis, selection bias may have influenced the re-
sults. Although comorbidity did not significantly influence the 
all-cause discontinuation rate in the current study, we cannot 
rule out the possibility that the clinician in this study may 
have paid more attention to these patients, because there was 
a lot of evidence with negative findings regarding the charac-
teristics of comorbidity in SAD. Also, the current study’s cli-
nician may have chosen SSRIs to manage a patient’s comor-
bid disorder, as SSRIs have a broader clinical indication with 
more evidence of efficacy against anxiety and depression. 
Fourth, many potentially relevant patient characteristics, so-
cio-economic factors, and treatment-related factors were not 
examined in this study.42 Lastly, we could not specify mean 
doses of medications due to several reasons. Doses of all 
medications in the current study were determined by clini-
cian judgment in a natural clinical setting. Therefore, the 
doses were changed for many reasons, such as a patient symp-
tom change or adverse effects during the long treatment period. 
Thus, future studies with more subjects and designed with 
prospective method are needed to confirm the relationships 
among treatment duration, types of medication, and other 
clinical variables in the pharmacotherapy of SAD. 
In conclusion, despite several limitations, the current study 
has clinical significance in that it demonstrated a difference 
in treatment adherence between the SSRIs and moclobemide 
in the pharmacotherapy of SAD in a natural clinical setting. 
The present results support the fact that SSRIs, which have 
better treatment adherence than moclobemide, may contrib-
ute to predictions of better treatment response in the pharma-
cotherapy of SAD in a natural clinical setting.
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